|
GB8808015D0
(en)
|
1988-04-06 |
1988-05-05 |
Ritter M A |
Chemical compounds
|
|
AU643427B2
(en)
|
1988-10-31 |
1993-11-18 |
Immunex Corporation |
Interleukin-4 receptors
|
|
BR9205967A
(pt)
|
1991-05-03 |
1994-07-26 |
Seragen Inc |
Moléculas marcadas com receptor de interleucina tratamento de artrite inflamatória
|
|
JP3315427B2
(ja)
|
1992-03-05 |
2002-08-19 |
大日本除蟲菊株式会社 |
皮膚炎治療剤
|
|
US5714146A
(en)
|
1992-08-26 |
1998-02-03 |
Board Of Regents Of The University Of Washington |
IL-4 bone therapy
|
|
EP0604693A1
(en)
|
1992-12-29 |
1994-07-06 |
Schering-Plough |
Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
|
|
RU2162711C2
(ru)
|
1993-09-07 |
2001-02-10 |
Смитклайн Бичам Корпорейшн |
Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
|
|
AU766492B2
(en)
|
1998-09-18 |
2003-10-16 |
Dynavax Technologies Corporation |
Methods of treating IgE-associated disorders and compositions for use therein
|
|
US6927044B2
(en)
|
1998-09-25 |
2005-08-09 |
Regeneron Pharmaceuticals, Inc. |
IL-1 receptor based cytokine traps
|
|
MXPA02011682A
(es)
|
2000-05-26 |
2003-05-14 |
Immunex Corp |
Uso de antagonistas de interleuquina-4 y composiciones de los mismos.
|
|
US7879328B2
(en)
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
|
CN100496579C
(zh)
|
2000-07-26 |
2009-06-10 |
株式会社凤凰堂 |
止痒性组合物和促进创伤治愈的组合物
|
|
PL366226A1
(en)
|
2000-12-22 |
2005-01-24 |
Societe Des Produits Nestle S.A. |
Induction of tolerance
|
|
US20030103938A1
(en)
|
2001-05-09 |
2003-06-05 |
Alk-Abello A/S |
Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
|
|
JP2004529180A
(ja)
|
2001-05-11 |
2004-09-24 |
ノバルティス アクチエンゲゼルシャフト |
ＩｇＥ関連障害を処置するのに使用するための組成物
|
|
ATE440617T1
(de)
|
2001-05-23 |
2009-09-15 |
Duotol Ab |
Unterdrückung von allergischen reaktionen durch transkutane verabreichung von allergenen zusammen mit oder fusioniert mit toxinuntereinheiten oder deren fragmenten
|
|
CA2468733C
(en)
|
2001-11-30 |
2013-06-11 |
Biogen Idec Ma Inc. |
Antibodies against monocyte chemotactic proteins
|
|
SI1527100T1
(sl)
|
2002-03-29 |
2009-12-31 |
Schering Corp |
Humana monoklonska protitelesa proti interlevkinu-5 in postopki in sestavki, ki jih obsegajo
|
|
AU2003280324A1
(en)
|
2002-11-26 |
2004-06-18 |
Alk-Abello A/S |
Pharmaceutical allergen product
|
|
EP1592777A4
(en)
|
2003-02-01 |
2008-06-04 |
Tanox Inc |
METHOD OF GENERATING HIGH-ANTIBODY ANTIBODIES
|
|
US7923209B2
(en)
|
2003-03-14 |
2011-04-12 |
Anergis, S.A. |
Allergen peptide fragments and use thereof
|
|
WO2005047331A2
(en)
|
2003-11-07 |
2005-05-26 |
Immunex Corporation |
Antibodies that bind interleukin-4 receptor
|
|
AU2004309373A1
(en)
|
2003-12-22 |
2005-07-14 |
Amgen Inc. |
Methods for identifying functional antibodies
|
|
ATE395358T1
(de)
|
2004-02-27 |
2008-05-15 |
Regeneron Pharma |
Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
|
|
AR049390A1
(es)
*
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
|
US20090098142A1
(en)
|
2004-06-09 |
2009-04-16 |
Kasaian Marion T |
Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
|
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
|
JP5234445B2
(ja)
|
2004-10-05 |
2013-07-10 |
源一郎 杣 |
薬剤
|
|
US8030003B2
(en)
|
2004-12-07 |
2011-10-04 |
Children's Hospital Medical Center |
Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
|
|
TW200902555A
(en)
|
2005-01-03 |
2009-01-16 |
Hoffmann La Roche |
Antibodies against IL-13 receptor alpha 1 and uses thereof
|
|
US7531637B2
(en)
|
2005-05-06 |
2009-05-12 |
Zymogenetics, Inc. |
IL-31 monoclonal antibodies
|
|
US8679545B2
(en)
|
2005-11-12 |
2014-03-25 |
The Regents Of The University Of California |
Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
|
|
US8324192B2
(en)
|
2005-11-12 |
2012-12-04 |
The Regents Of The University Of California |
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
|
|
PL2374818T3
(pl)
|
2006-06-02 |
2013-05-31 |
Regeneron Pharma |
Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
|
|
JP4221018B2
(ja)
|
2006-08-31 |
2009-02-12 |
トヨタ自動車株式会社 |
頭部保護エアバッグ装置
|
|
PL2069403T3
(pl)
|
2006-10-02 |
2015-08-31 |
Regeneron Pharma |
Przeciwciała ludzkie o wysokim powinowactwie wobec receptora ludzkiej IL-4
|
|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
RS53402B
(sr)
|
2007-03-22 |
2014-10-31 |
Genentech, Inc. |
Vezivanje apoptotskih anti-ige antitela za membranski ige
|
|
EP2022507A1
(en)
|
2007-08-07 |
2009-02-11 |
Universität Hamburg |
Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
|
|
WO2009061819A1
(en)
|
2007-11-05 |
2009-05-14 |
The Regents Of The University Of Colorado |
Minimally-invasive measurement of esophageal inflammation
|
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
|
DE202008006598U1
(de)
|
2008-04-11 |
2008-10-02 |
Alk-Abelló A/S |
Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
|
|
US20090264392A1
(en)
|
2008-04-21 |
2009-10-22 |
Meritage Pharma, Inc. |
Treating eosinophilic esophagitis
|
|
US20120004205A1
(en)
|
2008-12-01 |
2012-01-05 |
Cincinnati Children's Hospital Medical Center |
Il-13 induced gene signature for eosinophilic esophagitis
|
|
WO2010120524A2
(en)
|
2009-03-31 |
2010-10-21 |
Altair Therapeutics, Inc. |
Methods of modulating an immune response to a viral infection
|
|
US8497528B2
(en)
|
2010-05-06 |
2013-07-30 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Method for fabricating a strained structure
|
|
CA2773234C
(en)
|
2009-09-07 |
2017-11-28 |
Dbv Technologies |
Method of treating eosinophilic esophagitis
|
|
US8993347B2
(en)
*
|
2009-12-17 |
2015-03-31 |
Cornell University |
Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
|
|
ES2894936T3
(es)
|
2010-06-24 |
2022-02-16 |
Viropharma Biologics Llc |
Métodos de tratamiento para la inflamación del esófago
|
|
AU2011312191B2
(en)
|
2010-10-06 |
2015-07-02 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
|
|
KR101962483B1
(ko)
|
2010-11-17 |
2019-03-29 |
추가이 세이야쿠 가부시키가이샤 |
혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
|
|
RU2453303C1
(ru)
|
2010-12-23 |
2012-06-20 |
Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") |
Фармацевтическая композиция для лечения атопического дерматита
|
|
US20130324435A1
(en)
|
2011-01-06 |
2013-12-05 |
Children's Hospital Medical Center |
Esophageal cytokine expression profiles in eosinophilic esophagitis
|
|
US20130052190A1
(en)
|
2011-02-22 |
2013-02-28 |
Oxagen Limited |
CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
|
|
US9928344B2
(en)
|
2011-06-21 |
2018-03-27 |
Children's Hospital Medical Center |
Diagnostic methods of eosinophilic esophagitis
|
|
US8790651B2
(en)
|
2011-07-21 |
2014-07-29 |
Zoetis Llc |
Interleukin-31 monoclonal antibody
|
|
WO2013051928A1
(en)
|
2011-10-06 |
2013-04-11 |
N.V. Nutricia |
Treatment of eosinophilic esophagitis
|
|
SG11201402796SA
(en)
|
2011-12-16 |
2014-06-27 |
Atopix Therapeutics Ltd |
Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
|
|
TW201334789A
(zh)
|
2012-01-31 |
2013-09-01 |
Genentech Inc |
抗ｉｇｅ抗體及其使用方法
|
|
WO2013155010A1
(en)
|
2012-04-09 |
2013-10-17 |
Children's Hospital Medical Center |
Non-invasive biomarkers for eosinophilic esophagitis
|
|
JP6306588B2
(ja)
|
2012-08-21 |
2018-04-04 |
サノフィ・バイオテクノロジー |
Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
|
|
ES2981062T3
(es)
|
2012-09-07 |
2024-10-07 |
Regeneron Pharma |
Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R
|
|
US10132809B2
(en)
|
2012-10-10 |
2018-11-20 |
Rhote Island Hospital |
Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
|
|
US10077315B2
(en)
|
2013-02-05 |
2018-09-18 |
Engmab Sàrl |
Bispecific antibodies against CD3 and BCMA
|
|
TWI755763B
(zh)
|
2013-06-04 |
2022-02-21 |
美商再生元醫藥公司 |
藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
|
|
EP3010539B1
(en)
|
2013-06-21 |
2019-07-24 |
Sanofi Biotechnology |
Methods for treating nasal polyposis by administering an il-4r antagonist
|
|
TWI634900B
(zh)
|
2013-07-11 |
2018-09-11 |
再生元醫藥公司 |
藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
|
|
RU2552929C1
(ru)
|
2013-11-14 |
2015-06-10 |
Общество С Ограниченной Ответственностью "Фарминтерпрайсез" |
Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
|
|
IL315136A
(en)
|
2014-02-21 |
2024-10-01 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4rantagonist
|
|
EP3110848B1
(en)
|
2014-02-28 |
2024-02-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating skin infection by administering an il-4r antagonist
|
|
JP6861630B2
(ja)
|
2014-11-14 |
2021-04-21 |
サノフィ・バイオテクノロジー |
Ｉｌ−４ｒアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
|
|
US10314904B2
(en)
|
2016-02-19 |
2019-06-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
|
|
TWI777515B
(zh)
|
2016-08-18 |
2022-09-11 |
美商愛戴爾製藥股份有限公司 |
治療嗜伊紅性食道炎之方法
|
|
CN118141914A
(zh)
|
2016-09-01 |
2024-06-07 |
瑞泽恩制药公司 |
用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
|
|
US10485844B2
(en)
|
2016-09-22 |
2019-11-26 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
|
|
KR20190053250A
(ko)
|
2016-09-22 |
2019-05-17 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
|
|
MX2019009552A
(es)
|
2017-02-17 |
2019-10-02 |
Hutchinson Fred Cancer Res |
Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
US11053309B2
(en)
|
2017-08-04 |
2021-07-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating active eosinophilic esophagitis
|
|
EP4344706A3
(en)
|
2017-10-30 |
2024-05-22 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4r antagonist
|
|
MA52624A
(fr)
|
2018-05-13 |
2021-03-24 |
Regeneron Pharma |
Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
|
|
CN120665147A
(zh)
|
2018-06-14 |
2025-09-19 |
味之素株式会社 |
具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐
|
|
WO2020191346A1
(en)
|
2019-03-21 |
2020-09-24 |
Regeneron Pharmaceuticals, Inc. |
Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
|
|
EP3962515A1
(en)
|
2019-05-01 |
2022-03-09 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-33 antagonist
|
|
EP4010001A1
(en)
|
2019-08-05 |
2022-06-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
|
|
SG11202113310UA
(en)
|
2019-08-05 |
2021-12-30 |
Regeneron Pharma |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
AU2020399975A1
(en)
|
2019-12-09 |
2022-07-28 |
Sanofi Biotechnology |
Methods for treating digitally-identified IL-4/IL-13 related disorders
|
|
WO2021195530A1
(en)
|
2020-03-27 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
US20250154267A2
(en)
|
2020-05-22 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
|
|
US20220169739A1
(en)
|
2020-10-05 |
2022-06-02 |
Sanofi Biotechnology |
Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
|
|
US20220220211A1
(en)
|
2021-01-08 |
2022-07-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
|